NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:
The Pharmaceutical Market: UK
http://www.reportlinker.com/p0203096/The-Pharmaceutical-Market-UK.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
Espicom's highly regarded world pharmaceutical market reports
have been redesigned to provide enhanced strategic intelligence in
a user-friendly format. Each report provides in-depth information,
setting the pharmaceutical market in context. The reports
provide:
Five-year projections for economic, demographic, health
expenditure, health workforce and pharmaceutical market
indicators.
Specialised intelligence on OTCs, generics, biologics and
biosimilars.
Exclusive economic and demographic data from the Economist
Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health
expenditure, health infrastructure, health services and health
personnel.
The reports are updated quarterly, providing you with the latest
information for a full year. In addition, the service will keep you
up to date with market and industry news on a regular basis.
TABLE OF CONTENTS
EXECUTIVE SUMMARY 1
Snapshot: Strategic Espicom Analysis 2
Snapshot: Key Data Projections3
MACROENVIRONMENT 4
POLITICAL 4
ECONOMIC5
Projections 5
LEGAL6
EU Patent Protection & Intellectual Property Rights 6
Proposal for Unitary Patent 6
EU Supplementary Protection Certificates6
EU Data Exclusivity6
DEMOGRAPHIC 7
Projections 7
Demographic Indicators8
Births 8
Deaths 8
Infant Deaths 8
Life Expectancy at Birth 8
EPIDEMIOLOGY 9
DISEASE BURDEN 9
Leading Causes of Mortality9
DISEASE PREVALENCE10
Communicable Diseases 10
HIV/AIDS 10
Non-Communicable Diseases 11
Cancer 11
Diabetes 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12
EU DIRECTIVE12
Cross-Border Healthcare Directive 12
ORGANISATION 12
Performance 12
Structure 13
Department of Health 14
Strategic Health Authorities 14
Primary Care Trusts 14
Acute Trusts 14
NHS Foundation Trusts 14
NHS Care Trusts 15
Ambulance Trusts 15
Care Quality Commission 15
EXPENDITURE 17
Projections 17
NHS Budget 18
Private Healthcare 18
INFRASTRUCTURE 19
Hospital Infrastructure19
Private Hospital Operators19
BMI Healthcare 19
HCA International 19
Netcare 19
NHS Trusts 20
Nuffield Health 20
Partnership Health Group (PHG) 20
Ramsay Healthcare20
Spire Healthcare 20
Ambulatory Infrastructure21
SERVICES 21
Hospital Inpatient Services 21
Outpatient Services22
WORKFORCE 22
Projections 22
Physicians 23
Nurses 23
Dentists 24
Pharmacists 24
REGULATORY AFFAIRS 25
EU REGULATORY AUTHORITY 25
NATIONAL AUTHORITIES 25
MARKETING REGISTRATION 26
EU Marketing Registration26
Centralised Procedure 26
National Procedures 27
IMPORT REGULATIONS 27
Parallel Trade 27
PROMOTION 28
Advertising 28
PRICING & REIMBURSEMENT 29
EU NETWORKING MEETING 29
NM CAPR29
PRICING 29
PPRS Reforms 29
Patient Access Schemes 30
Prescription Charges 31
REIMBURSEMENT 31
DISTRIBUTION CHANNELS 34
EU DIRECTIVE 34
Falsified Medicines Directive34
DRUG WHOLESALING 34
Association of Wholesalers 34
BAPW34
Leading Wholesalers 35
AAH Pharmaceuticals 35
Alliance Healthcare35
DRUG RETAILING 36
Association of Independent Pharmacies 36
Numark36
Association of Community Pharmacies36
NPA 36
Leading Pharmacy Chains 37
Alliance Boots 37
Lloydspharmacy 37
Superdrug 37
MARKET ANALYSIS 38
SIZE 38
Projections 38
Historical Figures 40
Current Structure 41
PRODUCT DEVELOPMENT 49
EU Programmes49
Horizon 2020 49
IMI 49
National Research & Development 49
MANUFACTURING 52
TRADE53
Exports 53
Imports 56
Balance of Trade 60
COMPETITION 61
TRADE ASSOCIATIONS 61
ABPI 61
COMPANY INTELLIGENCE 62
AstraZeneca62
Eisai62
Eli Lilly 62
GlaxoSmithKline 62
MSD63
Novartis 63
Pfizer 64
ProStrakan64
Shire Pharmaceuticals 65
ViiV Healthcare 65
Competitive Strategies65
GLOBAL COMPANY INTELLIGENCE 66
AstraZeneca66
Company Overview 66
Financial Performance66
Product Portfolio 67
R&D Strategy 69
Manufacturing Capabilities 71
Outlook 71
GlaxoSmithKline 72
Company Overview 72
Financial Performance72
Product Portfolio 73
R&D Strategy 75
Manufacturing Capabilities 76
Outlook 76
Shire 77
Company Overview 77
Financial Performance78
Product Portfolio 79
R&D Strategy 80
Manufacturing Capabilities 81
OTC PHARMACEUTICALS 82
REGULATION 82
Marketing Registration 82
Labelling 82
MARKET SIZE 83
COMPETITION 84
Trade Association84
PAGB 84
GENERIC PHARMACEUTICALS 85
REGULATION 85
EU Marketing Registration85
Pricing & Reimbursement 85
Generic Substitution Plans are Scrapped 85
Unbranded Generic Pricing 85
2005 Generics Reimbursement Scheme 86
MARKET SIZE 87
COMPETITION 90
Trade Association90
BGMA90
Company Intelligence 90
Actavis 90
Bristol Laboratories90
Dr Reddy's 91
Kent Pharmaceuticals 91
Pfizer 91
Rosemont Pharmaceuticals 91
Teva Pharmaceuticals 91
Winthrop Pharmaceuticals 92
Wockhardt 92
BIOLOGICS & BIOSIMILARS 93
REGULATION 93
EU Approval Process 93
EU Regulation of Biosimilars 93
EMA Guideline Documents94
Draft Biosimilar Concept Paper94
Biosimilar mAb Guideline 94
Biosimilars Approved in the EU 95
National Regulation 95
NICE Approves First Biosimilar for NHS Use95
PRODUCT DEVELOPMENT 96
Cancer Research 96
Stem Cell Research 96
COMPETITION 97
Trade Association97
BIA 97
Company Intelligence 97
Angel Biotechnology97
Argenta 97
Ark Therapeutics 98
Astex Therapeutics98
BigDNA98
BioFocus 98
Biogen Idec 98
BTG 99
Cellartis99
Convergence Pharmaceuticals 99
FMC BioPolymer 99
ImmuPharma 99
Intercell 99
Lonza 100
NovaBiotics100
Oxford BioMedica100
PolyTherics 100
Silence Therapeutics 101
UCB 101
Competitive Strategies 101
CONCLUSIONS: OPPORTUNITIES & CHALLENGES 103
Strategic Espicom Analysis 103
MACROENVIRONMENT 103
EPIDEMIOLOGY 103
HEALTHCARE103
REGULATORY AFFAIRS104
PRICING & REIMBURSEMENT 104
DISTRIBUTION CHANNELS 105
MARKET 105
COMPETITION 106
OTC PHARMACEUTICALS 106
GENERIC PHARMACEUTICALS106
BIOLOGICS & BIOSIMILARS 106
Radar Analysis 108
SWOT Analysis 108
DIRECTORY 109
GOVERNMENT ORGANISATIONS 109
PHARMACEUTICAL COMPANIES 109
Biologic Companies 109
Generic Companies 109
PHARMACEUTICAL DISTRIBUTORS110
PHARMACY CHAINS 110
TRADE ORGANISATIONS110
List of Tables
Espicom Analysis of the Pharmaceutical Market, 2012 2
Key Data Projections, 2012-2017 3
Political Landscape, 2012 4
Regional Ranking of Projected Economies, 2017 5
Projected Economy, 2012-2017 5
Regional Ranking of Projected Demographics, 2017 7
Projected Demographics, 2012-2017 7
Demographic Indicators, 2002-2009 8
Causes of Death by Country, 2010 9
HIV and AIDS Cases, up to 2010 10
Regional Ranking of Projected Health Expenditure, 2017 17
Projected Health Expenditure, 2012-201717
Inpatient Procedures and Interventions by Type, 2010/11 21
Regional Ranking of Projected Physicians, 2017 22
Projected Physicians, 2012-2017 22
Consultants by Specialty in England, 2008-2010 23
NHS Nurses by Country, 2007-2009 23
Patient Access Schemes in Published Guidance, 2007-2010 30
NICE Appraisals in Development, January
2012 31
Members of BAPW, 2011 34
Celesio's Revenue from Wholesale Activities, 2007-2009 (Euro
Millions) 35
Alliance Healthcare's Financial Highlights, 2008-2010 (£
Millions) 35
Regional Ranking of Projected Pharmaceutical Markets, 2017
38
Projected Pharmaceutical Market at Retail Prices, 2012-2017
38
Historical Pharmaceutical Market at Retail Prices, 1995-2011
40
Written Prescriptions, 2006-2010 (Millions) 41
Prescriptions by Value, 2006-2010 (£ Millions) 41
Prescriptions & Cost by Therapeutic Area in the UK, 2010
42
Prescriptions & Cost by Therapeutic Area in England, 2010 43
Top 20 Prescribed Drugs in England by Value, 2010 44
Top 20 Prescribed Drugs in England by Volume, 2010 45
Cost of Pharmaceuticals Issued by Hospital Pharmacies in
England, 2003-2010 (£ Millions)
45
Prescriptions & Cost by Therapeutic Area in Wales, 2010 46
Prescriptions & Cost by Therapeutic Area in Scotland, 2010 47
Prescriptions & Cost by Therapeutic Area in Northern Ireland, 201048
Pharmaceutical R&D Expenditure, 1972-2007 (£ Millions)
50
Pharmaceutical Production, 1995-2010 (Euros 000s) 52
Pharmaceutical Exports by Category, 1995-2010 (US$000s) 53
Pharmaceutical Exports by Country/Region, 2010 (US$000s) 55
Pharmaceutical Imports by Category, 1995-2010 (US$000s) 56
Imports of Raw Materials by Country/Region, 2010 (US$000s)
58
Imports of Antisera & Vaccines by Country/Region, 2010
(US$000s) 58
Imports of Medicaments by Country/Region, 2010 (US$000s) 59
Balance of Pharmaceutical Trade, 1995-2010 (US$000s) 60
Full Members of the ABPI, 2011 61
AstraZeneca's Principal Operating Results, 2006-2010 (US$
Million) 66
AstraZeneca's Sales by Geographic Area, 2006-2010 (US$ Million)
67
AstraZeneca's Sales by Leading Products, 2006-2010 (US$
Million)68
AstraZeneca's Recent Product Approvals, 2010-2011 69
AstraZeneca's Major Manufacturing Facilities by Location, 2011
71
GSK's Principal Operating Results, 2006-2010 (£ Million) 73
GSK's Sales by Geographic Area, 2007-2010 (£ Million) 73
GSK's Sales by Leading Products, 2006-2010 (£ Million) 74
GSK's Recent Product Approvals, 2010-2011 75 Shire's Principal
Operating Results, 2006-2010 (US$ Million) 78
Shire's Revenue by Business Area, 2006-2010 (US$ Million) 78
Shire's Revenue by Geographic Area, 2006-2010 (US$ Million)
78
Shire's Revenue by Leading Products, 2006-2010 (US$ Million)
79
Shire's Recent Product Approvals, 2010-2011 80
Shire's Major Manufacturing Facilities by Location, 2011 81
OTC Sales at Retail Prices, 2007-2010 (£ Millions) 83
Full Members of PAGB, 2011 84
Prescriptions Written and Dispensed Generically in England by Value, 1996-2010 (£ Millions)
87
Prescriptions Written and Dispensed Generically in England by Volume, 1996-2010 (Millions) 88
Generic Prescribing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 88
Generic Dispensing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 89
Members of BGMA, 2011 90
Biosimilars Approved in the EU 95
Espicom Analysis of the Pharmaceutical Market, 2012 107
SWOT Analysis of the Pharmaceutical Market, 2012 108
List of Charts
Regional Comparison of Top 5 Projected Pharmaceutical Markets at
Retail Prices, 2017 39
Regional Comparison of Projected Pharmaceutical Market Share,
2017 39
Historical Pharmaceutical Market at Retail Prices,
1995-201140
Pharmaceutical Exports, 1995-2010 (US$ Billions) 54
Pharmaceutical Exports by Country/Region, 2010 (%) 54
Pharmaceutical Imports, 1995-2010 (US$ Billions) 56
Imports of Pharmaceuticals by Country/Region, 2010 (%) 57
Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)60
Radar Graph of the Pharmaceutical Market, 2012 108
To order this report:
Pharmaceutical Industry: The Pharmaceutical
Market: UK
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker